3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Endocrine
1
Conditions
Neuroendocrine Tumors
117
Gastro-enteropancreatic neuroendocrine tumor
21
Neoplasms
20
Carcinoid Tumor
17
Colorectal Neoplasms
13
Carcinoma, Neuroendocrine
11
Neoplasm Metastasis
10
Carcinoma
10
Lung Neoplasms
9
Small Cell Lung Carcinoma
8
Prostatic Neoplasms
8
Carcinoma, Renal Cell
8
Carcinoma, Non-Small-Cell Lung
8
Breast Neoplasms
8
Sarcoma
7
Pancreatic Neoplasms
7
Carcinoma, Hepatocellular
7
Adenoma, Islet Cell
7
Stomach Neoplasms
6
Serotonin Syndrome
6
Pheochromocytoma
6
Melanoma
6
Head and Neck Neoplasms
6
Digestive System Neoplasms
6
Cholangiocarcinoma
6
Thyroid Neoplasms
5
Paraganglioma
5
Ovarian Neoplasms
5
Gastroenteropancreatic Neuroendocrine Tumors
5
Colonic Neoplasms
5
Interventions
lanreotide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Flushing
×
NET
×
Clear all
NCT00774930
2022-10-14
ELECT
Ipsen
Phase 3
Completed
115 enrolled
17 charts